A preclinical xenograft model of prostate cancer using human tumors

Mitchell Graham Lawrence, Renea Anne Taylor, Roxanne Toivanen, John S Pedersen, Sam Norden, David William Pook, Mark Frydenberg, Australian Prostate Cancer BioResource, Melissa Papargiris, Birunthi Niranjan, Michelle Giustina Richards, Hong Wang, Anne T Collins, Norman J Maitland, Gail Petuna Risbridger

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Most cases of prostate cancer are now diagnosed as moderate-grade localized disease. These tumor specimens are important tools in the discovery and translation of prostate cancer research; however, unlike more advanced tumors, they are notoriously difficult to grow in the laboratory. We developed a system for efficiently xenografting localized human prostate cancer tissue, and we adapted this protocol to study the interactions between the specific subsets of epithelial and stromal cells. Fresh prostate tissues or isolated epithelial cells are recombined with mouse seminal vesicle mesenchyme (SVM) and grafted under the renal capsule of immunodeficient mice for optimum growth and survival. Alternatively, mouse mesenchyme can be replaced with human prostate fibroblasts in order to determine their contribution to tumor progression. Grafts can be grown for several months to determine the effectiveness of novel therapeutic compounds when administered to host mice, thereby paving the way for personalizing the treatment of individual prostate cancers.
Original languageEnglish
Pages (from-to)836 - 848
Number of pages13
JournalNature Protocols
Volume8
Issue number5
DOIs
Publication statusPublished - 2013

Cite this

Lawrence, Mitchell Graham ; Taylor, Renea Anne ; Toivanen, Roxanne ; Pedersen, John S ; Norden, Sam ; Pook, David William ; Frydenberg, Mark ; Australian Prostate Cancer BioResource ; Papargiris, Melissa ; Niranjan, Birunthi ; Richards, Michelle Giustina ; Wang, Hong ; Collins, Anne T ; Maitland, Norman J ; Risbridger, Gail Petuna. / A preclinical xenograft model of prostate cancer using human tumors. In: Nature Protocols. 2013 ; Vol. 8, No. 5. pp. 836 - 848.
@article{146def53bb5049ea869d11f4dd450b27,
title = "A preclinical xenograft model of prostate cancer using human tumors",
abstract = "Most cases of prostate cancer are now diagnosed as moderate-grade localized disease. These tumor specimens are important tools in the discovery and translation of prostate cancer research; however, unlike more advanced tumors, they are notoriously difficult to grow in the laboratory. We developed a system for efficiently xenografting localized human prostate cancer tissue, and we adapted this protocol to study the interactions between the specific subsets of epithelial and stromal cells. Fresh prostate tissues or isolated epithelial cells are recombined with mouse seminal vesicle mesenchyme (SVM) and grafted under the renal capsule of immunodeficient mice for optimum growth and survival. Alternatively, mouse mesenchyme can be replaced with human prostate fibroblasts in order to determine their contribution to tumor progression. Grafts can be grown for several months to determine the effectiveness of novel therapeutic compounds when administered to host mice, thereby paving the way for personalizing the treatment of individual prostate cancers.",
author = "Lawrence, {Mitchell Graham} and Taylor, {Renea Anne} and Roxanne Toivanen and Pedersen, {John S} and Sam Norden and Pook, {David William} and Mark Frydenberg and {Australian Prostate Cancer BioResource} and Melissa Papargiris and Birunthi Niranjan and Richards, {Michelle Giustina} and Hong Wang and Collins, {Anne T} and Maitland, {Norman J} and Risbridger, {Gail Petuna}",
year = "2013",
doi = "10.1038/nprot.2013.043",
language = "English",
volume = "8",
pages = "836 -- 848",
journal = "Nature Protocols",
issn = "1754-2189",
publisher = "Nature Publishing Group",
number = "5",

}

Lawrence, MG, Taylor, RA, Toivanen, R, Pedersen, JS, Norden, S, Pook, DW, Frydenberg, M, Australian Prostate Cancer BioResource, Papargiris, M, Niranjan, B, Richards, MG, Wang, H, Collins, AT, Maitland, NJ & Risbridger, GP 2013, 'A preclinical xenograft model of prostate cancer using human tumors', Nature Protocols, vol. 8, no. 5, pp. 836 - 848. https://doi.org/10.1038/nprot.2013.043

A preclinical xenograft model of prostate cancer using human tumors. / Lawrence, Mitchell Graham; Taylor, Renea Anne; Toivanen, Roxanne; Pedersen, John S; Norden, Sam; Pook, David William; Frydenberg, Mark; Australian Prostate Cancer BioResource; Papargiris, Melissa; Niranjan, Birunthi; Richards, Michelle Giustina; Wang, Hong; Collins, Anne T; Maitland, Norman J; Risbridger, Gail Petuna.

In: Nature Protocols, Vol. 8, No. 5, 2013, p. 836 - 848.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A preclinical xenograft model of prostate cancer using human tumors

AU - Lawrence, Mitchell Graham

AU - Taylor, Renea Anne

AU - Toivanen, Roxanne

AU - Pedersen, John S

AU - Norden, Sam

AU - Pook, David William

AU - Frydenberg, Mark

AU - Australian Prostate Cancer BioResource

AU - Papargiris, Melissa

AU - Niranjan, Birunthi

AU - Richards, Michelle Giustina

AU - Wang, Hong

AU - Collins, Anne T

AU - Maitland, Norman J

AU - Risbridger, Gail Petuna

PY - 2013

Y1 - 2013

N2 - Most cases of prostate cancer are now diagnosed as moderate-grade localized disease. These tumor specimens are important tools in the discovery and translation of prostate cancer research; however, unlike more advanced tumors, they are notoriously difficult to grow in the laboratory. We developed a system for efficiently xenografting localized human prostate cancer tissue, and we adapted this protocol to study the interactions between the specific subsets of epithelial and stromal cells. Fresh prostate tissues or isolated epithelial cells are recombined with mouse seminal vesicle mesenchyme (SVM) and grafted under the renal capsule of immunodeficient mice for optimum growth and survival. Alternatively, mouse mesenchyme can be replaced with human prostate fibroblasts in order to determine their contribution to tumor progression. Grafts can be grown for several months to determine the effectiveness of novel therapeutic compounds when administered to host mice, thereby paving the way for personalizing the treatment of individual prostate cancers.

AB - Most cases of prostate cancer are now diagnosed as moderate-grade localized disease. These tumor specimens are important tools in the discovery and translation of prostate cancer research; however, unlike more advanced tumors, they are notoriously difficult to grow in the laboratory. We developed a system for efficiently xenografting localized human prostate cancer tissue, and we adapted this protocol to study the interactions between the specific subsets of epithelial and stromal cells. Fresh prostate tissues or isolated epithelial cells are recombined with mouse seminal vesicle mesenchyme (SVM) and grafted under the renal capsule of immunodeficient mice for optimum growth and survival. Alternatively, mouse mesenchyme can be replaced with human prostate fibroblasts in order to determine their contribution to tumor progression. Grafts can be grown for several months to determine the effectiveness of novel therapeutic compounds when administered to host mice, thereby paving the way for personalizing the treatment of individual prostate cancers.

UR - http://www.nature.com/nprot/journal/v8/n5/pdf/nprot.2013.043.pdf

U2 - 10.1038/nprot.2013.043

DO - 10.1038/nprot.2013.043

M3 - Article

VL - 8

SP - 836

EP - 848

JO - Nature Protocols

JF - Nature Protocols

SN - 1754-2189

IS - 5

ER -